Opiant Pharmaceuticals (OPNT -0.3%) inks an agreement with Sanofi (SNY+0.5%) under which the latter will manufacture OPNT004 (drinabant), in development for the treatment of acute cannabinoid overdose.
The company intends to reformulate the cannabinoid receptor antagonist for parenteral administration in an emergency setting. It acquired exclusive global rights from Sanofi for this indication.
SNY will make the product at its site in Hungary.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.